Silo Pharma secures exclusive global license for stress-induced disorder drug SPC-15, nearing FDA submission for human trials.
Silo Pharma signs exclusive global license with Columbia University to develop, manufacture, and commercialize SPC-15, a drug candidate for stress-induced affective disorders and PTSD. The company is in the final stages before submitting an IND application to the FDA for first-in-human clinical trials. Silo CEO Eric Weisblum believes this step could increase shareholder value in the future.
July 08, 2024
3 Articles